Short article material
Canadian acquisition of a U.S.-based biotechnology business is the very first in STEMCELL’s history
VANCOUVER, British Columbia– STEMCELL Technologies, Canada’s biggest biotechnology business, is happy to reveal the acquisition of Propagenix Inc.– a Maryland-based biotechnology business concentrated on establishing innovations to allow brand-new techniques in regenerative medication.
Short article material
” The acquisition of Propagenix is an essential action in STEMCELL’s development journey and an accomplishment for Canada’s biotechnology market,” stated Dr. Allen Eaves, President and CEO, STEMCELL. “Propagenix’s innovation has the possible to add to huge improvements in clinical research study in both laboratories and medical settings for the treatment of cancer, air passage illness, and other conditions, and we are enjoyed invite its portfolio into STEMCELL’s item suite.”
Established in 2014, Propagenix has actually established and advertised special innovations, including its trademarked EpiX ⢠innovation. In 2017, STEMCELL certified the rights to EpiX ⢠for research study usage applications. This innovation has the possible to resolve medical requirements in changing a client’s own broken barrier tissues, like skin and digestive tract tissue, with crafted tissue options. The existing acquisition now allows STEMCELL to establish items based upon EpiX ⢠innovation for medical applications.
” We are thrilled that the incredible group of researchers at STEMCELL will guarantee Propagenix innovations and abilities for epithelial cell biology are released to their max to serve the life science research study neighborhood,” stated Dr. Brian Pollok on behalf of Propagenix co-founders.
STEMCELL’s acquisition consists of all of Propagenix’s properties and copyright portfolio, its existing service plans, along with its unique license to Conditional Reprogramming innovation with Georgetown University. Conditional Reprogramming permits researchers to grow growths and healthy tissue in lab settings for research study and has possible applications for regenerative medication and drug screening for individualized medication.
” With Propagenix’s innovation, STEMCELL anticipates supporting researchers who are advancing research study and establishing medical applications to eventually develop much better health results for clients being dealt with for particular illness,” stated Dr. Eaves.
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research study with more than 2,500 specialized reagents, tools, and services. STEMCELL provides premium cell culture media, cell separation innovations, instruments, accessory items, instructional resources, and agreement assay services that are utilized by researchers carrying out stem cell, immunology, cancer, regenerative medication, and cellular treatment research study worldwide.
View source variation on businesswire.com: https://www.businesswire.com/news/home/20240119648511/en/
Contacts
Media
To learn more and to set up an interview, contact:
Ryan-Sang Lee
Senior Supervisor, Corporate Communications, STEMCELL Technologies
[email protected]
#distro
Share this short article in your social media network